Alzheimer's Society volunteer Chantal Clairicia explains how, following her mum Armelle's dementia diagnosis, reminiscence therapy took her family on an emotional journey to explore their roots in Guadeloupe.
Alzheimer's Society volunteer Chantal Clairicia explains how, following her mum Armelle's dementia diagnosis, reminiscence therapy took her family on an emotional journey to explore their roots in Guadeloupe.
Alzheimer's Society, study participant Eric Deeson and Sir Prof John Hardy comment on the disappointing clinical trial results for Alzheimer's drug gantenerumab.
Yesterday (27 September 2022), Eisai Co. Ltd. and Biogen announced top-line results for a major trial on the drug lecanemab in slowing down the progress of Alzheimer’s disease. Alzheimer's Society comments on this Alzheimer’s progression drug hope.
Aducanumab is a drug that has been developed as a potential treatment for Alzheimer’s disease. Find out more about the drug, its path to approval in the US, and what it means for people with dementia in the UK.
Aducanumab is a drug that has been developed as a potential treatment for Alzheimer’s disease. Find out more about the drug, its path to approval in the US, and what it means for people with dementia in the UK.
...
The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. The drug was previously approved for use in the US by the Food and Drug Administration (FDA) on 7 June 2021.
James is a young artist with autism who helps to care for his grandmother, Joan. She moved in with James and his mum when the first coronavirus lockdown made Joan isolated and confused. Now Joan, who has vascular dementia, and James are regularly enjoying artistic activities together and both benefit from them.
James is a young artist with autism who helps to care for his grandmother, Joan. She moved in with James and his mum when the first coronavirus lockdown made Joan isolated and confused. Now Joan, who has vascular dementia, and James are regularly enjoying artistic activities together and both benefit from them.
...
Researchers presented results from a phase 3 trial of pimavanserin that showed a significant reduction in the risk of relapse into psychosis compared to the placebo.
Biogen presented their results on Aducanumab, their newest drug for the treatment of Alzheimer's disease at the CTAD conference 2019 in San Diego, USA.
Dementia Support Line